Bayer Schering Pharma AG has submitted an application for registration of a new formulation of Levitra® (vardenafil HCI) in the European Union (EU). This new formulation is an orodispersible tablet containing 10mg vardenafil. In contrast to other drugs of the same class used for the treatment of erectile dysfunction, Levitra orodispersible tablet allows men a discreet and convenient intake without water, dissolving on the tongue within seconds.

"Erectile dysfunction is a troublesome condition that may heavily impact men's well-being and their relationship", said Jean-Philippe Milon, Ph.D., Head of Bayer Schering Pharma's business unit General Medicine. "With the submission of this new formulation of Levitra, we have reached another important strategic milestone in the development of innovative and easy-to-use men's health products."

The efficacy and safety of Levitra 10mg orodispersible tablet have been demonstrated in two large clinical Phase III studies. The new formulation has shown in all studies the same efficacy and safety as the currently available tablet.